Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 303.47M | 228.26M | 217.77M | 187.51M | 190.19M | 175.69M |
Gross Profit | 268.17M | 214.71M | 208.18M | 178.13M | 186.62M | 170.98M |
EBITDA | 306.53M | 211.54M | 145.80M | 162.81M | 161.96M | 157.38M |
Net Income | 219.74M | 125.08M | 53.73M | 42.87M | 48.30M | 57.21M |
Balance Sheet | ||||||
Total Assets | 4.66B | 3.44B | 2.08B | 1.62B | 1.64B | 1.50B |
Cash, Cash Equivalents and Short-Term Investments | 306.05M | 213.82M | 294.45M | 13.18M | 19.89M | 18.92M |
Total Debt | 0.00 | 396.93M | 595.60M | 719.50M | 673.40M | 545.59M |
Total Liabilities | 1.33B | 507.63M | 666.12M | 771.41M | 725.09M | 589.42M |
Stockholders Equity | 3.30B | 2.91B | 1.42B | 849.37M | 915.76M | 914.14M |
Cash Flow | ||||||
Free Cash Flow | 301.10M | 236.20M | 143.79M | 137.12M | 150.86M | 137.44M |
Operating Cash Flow | 314.61M | 244.25M | 154.77M | 144.41M | 156.87M | 145.74M |
Investing Cash Flow | -1.86B | -1.51B | -267.81M | -127.40M | -192.63M | -41.58M |
Financing Cash Flow | 1.36B | 1.19B | 394.32M | -23.73M | 36.74M | -105.56M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | $7.47B | 28.28 | 8.36% | 3.69% | 50.84% | 104.44% | |
77 Outperform | $3.54B | 23.84 | 10.49% | 4.82% | 6.87% | 7.23% | |
74 Outperform | $4.43B | 24.28 | 6.66% | 6.50% | 6.89% | 240.70% | |
72 Outperform | $6.90B | ― | -1.51% | 2.47% | 11.62% | ― | |
71 Outperform | ¥233.02B | 14.83 | 10.65% | 3.47% | 19.64% | 27.23% | |
61 Neutral | $5.79B | ― | -7.59% | 7.10% | -7.16% | 23.40% | |
51 Neutral | $2.43B | ― | -25.97% | 7.90% | 27.66% | 18.03% |
On August 12, 2025, CareTrust REIT, Inc. entered into an underwriting agreement with major financial institutions to sell 20,000,000 shares of its common stock at $32.00 per share, with an option for an additional 3,000,000 shares, which was fully exercised the next day. The issuance of these shares, completed on August 14, 2025, was part of a strategic move to enhance the company’s financial positioning and potentially expand its operations within the healthcare real estate sector.
The most recent analyst rating on (CTRE) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on CareTrust REIT stock, see the CTRE Stock Forecast page.
CareTrust REIT reported its second quarter 2025 results, highlighting significant investments totaling $1.1 billion, including the acquisition of Care REIT plc, and an upsized credit facility. The company achieved a net income of $68.5 million and maintained a strong financial position with a net debt-to-annualized normalized run rate EBITDA of 2.0x. CareTrust also increased its 2025 financial guidance, projecting higher net income and FFO per share, while maintaining a quarterly dividend payout ratio of approximately 78%. The strategic acquisition of Care REIT marked CareTrust’s entry into the UK market, broadening its operator bench and diversifying its asset mix, payor base, and geographic reach.
The most recent analyst rating on (CTRE) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on CareTrust REIT stock, see the CTRE Stock Forecast page.
On May 30, 2025, CareTrust REIT, Inc. entered into an amendment to its credit and guaranty agreement, introducing a $500 million unsecured term loan facility alongside its existing $1.2 billion revolving credit facility. This move is expected to help the company pay off existing debt, fund acquisitions, and support general corporate purposes, potentially enhancing its financial flexibility and positioning in the healthcare real estate market.
The most recent analyst rating on (CTRE) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on CareTrust REIT stock, see the CTRE Stock Forecast page.
CareTrust REIT, Inc. has released an updated investor presentation available on their website. The company clarifies that this update is not mandated by securities laws and does not include undisclosed material investor information.
The most recent analyst rating on (CTRE) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on CareTrust REIT stock, see the CTRE Stock Forecast page.